General
Preferred name
SULFADIAZINE
Synonyms
Silver sulfadiazine ()
SULFAMERAZINE ()
Sulphadiazine ()
SULFADIAZINE, SILVER ()
Sulfadiazine component of terfonyl ()
Sulfadiazine (trisulfapyrimidines) component of terfonyl ()
Diazyl ()
Sulfolex ()
NSC-35600 ()
Coco-diazine ()
Sulfadiazine component of sulfaloid ()
Sulfadiazina ()
Sulfadiazine component of sulfonamides duplex ()
Sulfadiazine component of sulfose ()
Sulfadiazine (trisulfapyrimidines) component of neotrizine ()
Trisulfapyrimidines (sulfadiazine) ()
Sulfadiazine component of neotrizine ()
Sulfadiazine component of triple sulfoid ()
Sulfadiazine (trisulfapyrimidines) ()
Sulfadiazine component of lantrisul ()
Ssd Af ()
Thermazene ()
Silver sulphadiazine ()
Sildaflo ()
Silvazine ()
Dermazin ()
Sulfadiazinum argentum ()
Sulfadiazine Silver ()
Sulfadiazine silver salt ()
Altreet-ag ()
Flamazine ()
Silvadene ()
Silver Sulfadiazine ()
Flammacerium ()
Sulfadiazine-d4 ()
P&D ID
PD001750
CAS
68-35-9
141582-64-1
22199-08-2
1020719-78-1
Tags
available
drug
Approved by
FDA
First approval
1941
1973
Drug indication
Rheumatic fever
infection
Bacterial infection
osteomyelitis
Drug Status
vet_approved
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Sulfadiazine is a sulfonamide with broad-spectrum antimicrobial activity . It is used in the treatment of toxoplasmosis, an infection with the protozoan parasite Toxoplasma gondi that can cause serious complications during pregnancy and in patients with weakened immune systems. Dermatological formulations containing silver sulfadiazine (PubChem CID 441244) are used to prevent and treat wound infections. (GtoPdb)
DESCRIPTION Sulfadiazine is a sulfonamide antibiotic with antimalarial activity. Sulfadiazine can be used for toxoplasmosis research[1][2].
PRICE 29
TOXICITY Acute oral toxicity (LD50) in rat is 10001 mg/kg.;
MOA Studies utilizing radioactive micronized silver sulfadiazine, electron microscopy, and biochemical techniques have revealed that the mechanism of action of silver sulfadiazine on bacteria differs from silver nitrate and sodium sulfadiazine. Silver sulfadiazine acts only on the cell membrane and cell wall to produce its bactericidal effect. A specific mechanism of action has not been determined, but silver sulfadiazine's effectiveness may possibly be from a synergistic interaction, or the action of each component. Silver is a biocide, which binds to a broad range of targets. Silver ions bind to nucleophilic amino acids, as well as sulfhydryl, amino, imidazole, phosphate, and carboxyl groups in proteins, causing protein denaturation and enzyme inhibition. ; Silver binds to surface membranes and proteins, causing proton leaks in the membrane, leading to cell death. ; Sulfadiazine is a competitive inhibitor of bacterial para-aminobenzoic acid (PABA), a substrate of the enzyme dihydropteroate synthetase. The inhibited reaction is necessary in these organisms for the synthesis of folic acid.
PRICE 29
DESCRIPTION Silver sulfadiazine (Dermazin) is a sulfonamide-based topical agent with antibacterial and antifungal activity.
DESCRIPTION Sulfadiazine is a sulfonamide antibiotic. It inhibits dihydropteroate synthase (DHPS). It is used for the treatment of a variety of infections, such as urinary tract infections, trachoma, and chancroid. (Enamine Bioactive Compounds)
DESCRIPTION Sulfadiazine (Sulphadiazine) is a synthetic pyrimidinyl sulfonamide derivative, short-acting bacteriostatic Sulfadiazine inhibits bacterial folic acid synthesis by competing with para-aminobenzoic acid. It is used in combination with pyrimethamine to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections. (TargetMol Bioactive Compound Library)
Cell lines
1
Organisms
5
Compound Sets
23
Cayman Chemical Bioactives
23719
33605
ChEMBL Approved Drugs
CHEMBL439
CHEMBL1382627
ChEMBL Drugs
CHEMBL439
CHEMBL1382627
Drug Repurposing Hub
DrugBank
DB00359
DB05245
DrugBank Approved Drugs
DB00359
DB05245
DrugCentral
2500
DrugCentral Approved Drugs
2500
DrugMAP
DMTW3R8
DMVTHWQ
DrugMAP Approved Drugs
DMTW3R8
DMVTHWQ
DrugMatrix
Enamine Bioactive Compounds
EBC-03731
Enamine BioReference Compounds
Guide to Pharmacology
12635
MedChem Express Bioactive Compound Library
HY-B0273
NCATS Inxight Approved Drugs
0N7609K889
W46JY43EJR
NPC Screening Collection
Other bioactive compounds
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
Sulfadiazine
TargetMol Bioactive Compound Library
T0930
The Spectrum Collection
External IDs
98
Properties
(calculated by RDKit )
Molecular Weight
250.05
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
2
Rotatable Bonds
3
Ring Count
2
Aromatic Ring Count
2
cLogP
0.86
TPSA
97.97
Fraction CSP3
0.0
Chiral centers
0.0
Largest ring
6.0
QED
0.79
QED
0.79
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Indication
malaria, meningitis, urinary tract infections, conjunctivitis, trachoma, chancroid
Disease Area
infectious disease, ophthalmology
MOA
bacterial antifolate
Pathway
Autophagy
Microbiology/virology
Anti-infection
Target
antibiotic
Bacterial
Parasite
Antibiotics
DHPS
Therapeutic Class
Antiinfective Agents
Source data